I believe Dr. Thornton is well aware that TNFerade works, he also knows of Dr. Vincent Picozzi's criticism of the PACT Protocol, and about the protocol that Dr. Picozzi wanted to run. In short, when I met Dr. Picozzi he wouldn't give me specifics about his protocol, but assured me that management was well aware of it, and his misgivings on PACT, I should have taken his warning more seriously, but he did indicate a possibility that PACT taken to conclusion potentially could gain approval.
Unfortunately, I don't believe anyone took into account the advantage of adding drugs like Abraxane to the SOC, but clearly it should be approved for Pancreatic Cancer. The question is, would TNFerade further enhance what it's capable of.
By the way, TNFerade is currently not out of the Pancreatic venue completely, we should know a some point this year if the small trial being conducted with another trial with limited mets in combination with another experimental drug produces results superior to the other drug alone. If it does, and if together the results are better than the SOC, we could be back in business in Pancreatic Cancer quicker then anyone thinks.
For now, Dr. Thornton may be the scapegoat for the failure, but listening to Dr. Picozzi, he may have been responsible for a trial protocol that was destined to fail, perhaps letting him go was the right thing to do.
Gary
